New imaging agent could predict cancer drug success
NCT ID NCT05065736
First seen Mar 20, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-stage study tests a new PET imaging agent, 18F-Clofarabine, to measure an enzyme (DCK) activity in metastatic cancers. The goal is to see if this scan can predict whether drugs like gemcitabine will be taken up by cancer cells. About 4 adults with metastatic cancer will receive the tracer and undergo PET/CT scans. This is a diagnostic study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.